A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorShanghai Cell Therapy Group Co.,Ltd
About this trial
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.
Eligibility criteria
Qualifiers
Understand and voluntarily sign an informed consent form (ICF) before conducting any research related evaluations/procedures;
Age range: 18-75 years old;
Expected survival period is not less than 12 weeks;
ECOG score ≤ 2 points;
Disqualifiers
Asymptomatic (smoking type) multiple myeloma;
Multiple myeloma with only extramedullary lesions present;
Plasma cell leukemia;
Merge amyloidosis;
Trial design
Treatments tested in this trial
- CD19/CD20/BCMA CAR-T
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov